SS Rajamouli on Tuesday announced that he will be presenting the upcoming feature film Made In India, a biopic on 'Father of Indian Cinema' Dadasaheb Phalke.
The RRR filmmaker said the script moved him emotionally when he heard the narration.
"When I first heard the narration, it moved me emotionally like nothing else. Making a biopic is tough in itself, but conceiving one about the FATHER OF INDIAN CINEMA is even more challenging. Our boys are ready and up for it.. With immense pride, Presenting 'MADE IN INDIA'," Rajamouli wrote on X, formerly known as Twitter.
He also shared the announcement teaser, which described the upcoming feature as the "biopic of Indian cinema".
"Made In India" will be directed by Nitin Kakkar, known for films such as "Filmistaan", "Mitron" and "Jawaani Jaaneman". The venture also marks Rajamouli's son SS Karthikeya's debut as a film producer. He was credited as the line producer of RRR.
"It’s been years since I wanted to fulfill my dream of becoming a producer. The moment has come. 'MADE IN INDIA'... With utmost responsibility, taking this up as a challenge," Karthikeya wrote on X, Varun Gupta is also attached as a producer.
Dadasaheb Phalke, referred to as the ‘Father of Indian Cinema’, made the first-ever full-length Indian feature film titled "Raja Harishchandra" in 1913. Born in Trimbak in present-day Maharashtra, the filmmaker's real name was Dhundiraj Govind Phalke.
He went to London to learn filmmaking from Cecil Hepworth and made his directorial debut in 1913 with "Raja Harishchandra", India's first full-length feature. In his career spanning over 19 years, he made 95 movies and 27 short films.
In 1969, the central government paid homage to the visionary filmmaker by dedicating an award in his name, Dadasaheb Phalke Award, which recognises lifetime contributions to Indian cinema.
Made In India marks Rajamouli's first project as a presenter after the global success of his Telugu period action drama RRR, which won the best original song award for "Naatu Naatu" at the Academy Awards earlier this year.
The makers are yet to announce the cast and other details about the film.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.